-
1.发明授权EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR 有权酪氨酸激酶受体的胞外变构抑制剂结合域
公开(公告)号：EP2448964B1
公开(公告)日：2017-04-12
申请号：EP10734333.7
申请日：2010-07-02
发明人： CARMELIET, Peter , DE SMET, Frederik , SCHYMKOWITZ, Joost , ROUSSEAU, Frédéric , HERBERT, Corentin
IPC分类号： C07K14/71 , A61K31/4745
CPC分类号： A61K31/437 , C07K14/71 , G01N2500/02
-
2.发明公开EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR 有权Ext re che che che che or or or or or or or or or or or or or or
公开(公告)号：EP2448964A1
公开(公告)日：2012-05-09
申请号：EP10734333.7
申请日：2010-07-02
发明人： CARMELIET, Peter , DE SMET, Frederik , SCHYMKOWITZ, Joost , ROUSSEAU, Frédéric , HERBERT, Corentin
IPC分类号： C07K14/71 , A61K31/4745
CPC分类号： A61K31/437 , C07K14/71 , G01N2500/02
摘要： The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
摘要翻译： 本发明涉及变构抑制剂的细胞外结合结构域，其中所述结合结构域衍生自单个跨膜酪氨酸激酶受体。 更具体地，本发明涉及来自成纤维细胞生长因子受体（FGFR）的细胞外结构域。 它进一步涉及该领域用于鉴定其它酪氨酸激酶受体细胞外部分中类似结构域的用途，以及用于鉴定变构抑制剂的筛选方法。
-
3.发明公开
公开(公告)号：EP2590976A1
公开(公告)日：2013-05-15
申请号：EP11743633.7
申请日：2011-07-04
申请人： SANOFI
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： A61K31/517 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/437 , A61K31/5377 , A61K45/06 , C07D211/82 , C07D211/90 , C07D233/64 , C07D233/88 , C07D233/90 , C07D471/04
摘要： The invention relates to compounds corresponding to formula (I): R4 NN R1 O R2 R3 (I) 5 6 7 8 in which - R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc' (A) (B) (C) in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.
-
4.发明授权
公开(公告)号：EP2590976B1
公开(公告)日：2015-09-16
申请号：EP11743633.7
申请日：2011-07-04
申请人： SANOFI
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： A61K31/517 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/437 , A61K31/5377 , A61K45/06 , C07D211/82 , C07D211/90 , C07D233/64 , C07D233/88 , C07D233/90 , C07D471/04
-
公开(公告)号：EP2315781A2
公开(公告)日：2011-05-04
申请号：EP09784478.1
申请日：2009-07-07
申请人： Sanofi-Aventis
发明人： BAURIN, Nicolas , BERNE, Pierre-François , BLANCHE, Francis , BONO, Françoise , CAMERON, Béatrice , DABDOUBI, Tarik , HERBERT, Corentin , MIKOL, Vincent , REMY, Elisabeth
IPC分类号： C07K16/28 , C12N15/13 , C12N5/18 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/303 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention relates to FGF-R4 receptor-specific antagonist molecules enabling the inhibition of the activity of said receptor. Said antagonists are, particularly, FGF-R4-specific antibodies enabling the inhibition of the activity of said receptor. The present invention also relates to the therapeutic use of said antibodies, particularly in the field of angiogenesis and in the treatment of certain types of cancer.
-
6.发明授权
公开(公告)号：EP2590975B1
公开(公告)日：2015-08-19
申请号：EP11743363.1
申请日：2011-07-04
申请人： SANOFI
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D207/32 , C07D207/36 , C07D211/82
-
公开(公告)号：EP2800566A1
公开(公告)日：2014-11-12
申请号：EP13702101.0
申请日：2013-01-03
申请人： SANOFI
IPC分类号： A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K31/437
摘要： The invention relates to the use of compounds corresponding to formula (I) in which R
2 and R
3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of the formulae (A), (B) and (C) in which the wavy lines represent the phenyl nucleus to which R
2 and R
3 are attached, or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer.-
8.发明公开
公开(公告)号：EP2590975A1
公开(公告)日：2013-05-15
申请号：EP11743363.1
申请日：2011-07-04
申请人： SANOFI
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D207/32 , C07D207/36 , C07D211/82
摘要： The invention relates to compounds corresponding to formula (I): N R1 O R3 R4 R2 (I) in which - R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc' (A) (B) (C) in which the wavy lines represent the phenyl nucleus to which R3 and R4 are attached. Preparation process and therapeutic use.
-
公开(公告)号：EP2800566B1
公开(公告)日：2015-10-28
申请号：EP13702101.0
申请日：2013-01-03
申请人： SANOFI
IPC分类号： A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K31/437
-
公开(公告)号：EP2315781B1
公开(公告)日：2015-05-06
申请号：EP09784478.1
申请日：2009-07-07
申请人： SANOFI
发明人： BAURIN, Nicolas , BERNE, Pierre-François , BLANCHE, Francis , BONO, Françoise , CAMERON, Béatrice , DABDOUBI, Tarik , HERBERT, Corentin , MIKOL, Vincent , REMY, Elisabeth
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/303 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.022 秒)
